1832 Asset Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-105,199
| Closed | -$7.79M | – | 672 |
|
|
2024
Q4 | $7.79M | Sell |
105,199
-150,245
| -59% | -$10.5M | 0.01% | 337 |
|
|
2024
Q3 | $16.9M | Sell |
255,444
-22,014
| -8% | -$1.6M | 0.01% | 302 |
|
|
2024
Q2 | $25.6M | Sell |
277,458
-29,839
| -10% | -$2.64M | 0.02% | 253 |
|
|
2024
Q1 | $29.4M | Sell |
307,297
-385,935
| -56% | -$32.4M | 0.02% | 226 |
|
|
2023
Q4 | $52.9M | Sell |
693,232
-107,143
| -13% | -$7.46M | 0.08% | 176 |
|
|
2023
Q3 | $55.4M | Buy |
800,375
+23,095
| +3% | +$1.86M | 0.08% | 158 |
|
|
2023
Q2 | $73.3M | Sell |
777,280
-34,115
| -4% | -$2.97M | 0.09% | 134 |
|
|
2023
Q1 | $67.1M | Buy |
811,395
+5,865
| +0.7% | +$461K | 0.1% | 156 |
|
|
2022
Q4 | $60.1M | Sell |
805,530
-39,925
| -5% | -$3.08M | 0.1% | 168 |
|
|
2022
Q3 | $69.9M | Sell |
845,455
-15,295
| -2% | -$1.47M | 0.13% | 150 |
|
|
2022
Q2 | $81.8M | Sell |
860,750
-13,846
| -2% | -$1.43M | 0.14% | 134 |
|
|
2022
Q1 | $102M | Buy |
874,596
+118,765
| +16% | +$13.3M | 0.14% | 126 |
|
|
2021
Q4 | $99.5M | Sell |
755,831
-655,093
| -46% | -$76.4M | 0.18% | 119 |
|
|
2021
Q3 | $161M | Sell |
1,410,924
-179,516
| -11% | -$20.5M | 0.3% | 88 |
|
|
2021
Q2 | $164M | Buy |
1,590,440
+957,333
| +151% | +$90.2M | 0.32% | 86 |
|
|
2021
Q1 | $52.7M | Buy |
633,107
+2,675
| +0.4% | +$226K | 0.11% | 167 |
|
|
2020
Q4 | $56.8M | Sell |
630,432
-60,870
| -9% | -$5.05M | 0.13% | 146 |
|
|
2020
Q3 | $54.6M | Buy |
+691,302
| New | +$53.9M | 0.14% | 133 |
|
|
2020
Q2 | – | Sell |
-238,152
| Closed | -$15.6M | – | 671 |
|
|
2020
Q1 | $15.6M | Sell |
238,152
-29,820
| -11% | -$2.15M | 0.06% | 198 |
|
|
2019
Q4 | $20.9M | Buy |
267,972
+137,607
| +106% | +$10.7M | 0.06% | 187 |
|
|
2019
Q3 | $9.44M | Buy |
130,365
+122,169
| +1,491% | +$8.58M | 0.03% | 234 |
|
|
2019
Q2 | $507K | Buy |
8,196
+8,100
| +8,438% | +$490K | ﹤0.01% | 500 |
|
|
2019
Q1 | $6K | Hold |
96
| – | – | ﹤0.01% | 590 |
|
|
2018
Q4 | $5K | Hold |
96
| – | – | ﹤0.01% | 582 |
|
|
2018
Q3 | $6K | Hold |
96
| – | – | ﹤0.01% | 607 |
|
|
2018
Q2 | $5K | Buy |
+96
| New | +$4.48K | ﹤0.01% | 603 |
|
|
2018
Q1 | – | Sell |
-60
| Closed | -$2K | – | 691 |
|
|
2017
Q4 | $2K | Buy |
+60
| New | +$2.2K | ﹤0.01% | 662 |
|
|
2017
Q2 | – | Sell |
-7,875
| Closed | -$247K | – | 683 |
|
|
2017
Q1 | $247K | Buy |
7,875
+1,281
| +19% | +$40.1K | ﹤0.01% | 526 |
|
|
2016
Q4 | $206K | Sell |
6,594
-1,716,006
| -100% | -$55.6M | ﹤0.01% | 506 |
|
|
2016
Q3 | $67.3M | Buy |
+1,722,600
| New | +$64.9M | 0.25% | 98 |
|
Other funds holding EW
1832 Asset Management's EW Position: Q1 2025 in Review
1832 Asset Management sold out of Edwards Lifesciences (EW) in Q1 2025, closing a stake of 105,199 shares — an estimated $7.79M sold.
1832 Asset Management first reported a position in EW in Q3 2016 and held it in 30 quarters. The position peaked at $164M in Q2 2021. 1,206 funds tracked by Wall St. Rank hold EW as of Q1 2025.
- 1832 Asset Management reported no remaining Edwards Lifesciences position as of Q1 2025 after selling out during the quarter.
- 1832 Asset Management sold 105,199 Edwards Lifesciences shares in Q1 2025, an estimated $7.79M.
- 1832 Asset Management first reported a position in Edwards Lifesciences in Q3 2016 and held it in 30 quarters.
- 1832 Asset Management's Edwards Lifesciences position peaked at $164M in Q2 2021.
- 1,206 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2025.
Based on 1832 Asset Management's 13F filing for Q1 2025, filed 14 May 2025.